Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Share-based Compensation (2023 - 2025)

CG Oncology (CGON) has disclosed Share-based Compensation for 3 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 44.03% year-over-year to $7.2 million, compared with a TTM value of $26.7 million through Dec 2025, up 133.96%, and an annual FY2025 reading of $26.7 million, up 133.96% over the prior year.
  • Share-based Compensation was $7.2 million for Q4 2025 at CG Oncology, down from $7.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.3 million in Q3 2025 and bottomed at $177000.0 in Q2 2023.
  • Average Share-based Compensation over 3 years is $3.3 million, with a median of $2.4 million recorded in 2024.
  • The sharpest move saw Share-based Compensation soared 1168.93% in 2024, then skyrocketed 44.03% in 2025.
  • Year by year, Share-based Compensation stood at $778000.0 in 2023, then skyrocketed by 541.39% to $5.0 million in 2024, then surged by 44.03% to $7.2 million in 2025.
  • Business Quant data shows Share-based Compensation for CGON at $7.2 million in Q4 2025, $7.3 million in Q3 2025, and $7.0 million in Q2 2025.